Search Results - "Egger, Jacklynn"

Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers by Luo, Jia, Rizvi, Hira, Egger, Jacklynn V, Preeshagul, Isabel R, Wolchok, Jedd D, Hellmann, Matthew D

“…The coronavirus disease 2019 (COVID-19) pandemic has led to dramatic changes in oncology practice. It is currently unknown whether programmed death 1 (PD-1)…”
Get more information

Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer by Luo, Jia, Martucci, Victoria L, Quandt, Zoe, Groha, Stefan, Murray, Megan H, Lovly, Christine M, Rizvi, Hira, Egger, Jacklynn V, Plodkowski, Andrew J, Abu-Akeel, Mohsen, Schulze, Isabell, Merghoub, Taha, Cardenas, Eduardo, Huntsman, Scott, Li, Min, Hu, Donglei, Gubens, Matthew A, Gusev, Alexander, Aldrich, Melinda C, Hellmann, Matthew D, Ziv, Elad

“…Genetic differences in immunity may contribute to toxicity and outcomes with immune checkpoint inhibitor (CPI) therapy, but these relationships are poorly…”
Get full text

Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation by Rudin, Charles M, Balli, David, Lai, W Victoria, Richards, Allison L, Nguyen, Evelyn, Egger, Jacklynn V, Choudhury, Noura J, Sen, Triparna, Chow, Andrew, Poirier, John T, Geese, William J, Hellmann, Matthew D, Forslund, Ann

“…A small percentage of patients with SCLC experience durable responses to immune checkpoint blockade (ICB). Defining determinants of immune response may…”
Get more information

Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer by Vanguri, Rami S, Luo, Jia, Aukerman, Andrew T, Egger, Jacklynn V, Fong, Christopher J, Horvat, Natally, Pagano, Andrew, Araujo-Filho, Jose de Arimateia Batista, Geneslaw, Luke, Rizvi, Hira, Sosa, Ramon, Boehm, Kevin M, Yang, Soo-Ryum, Bodd, Francis M, Ventura, Katia, Hollmann, Travis J, Ginsberg, Michelle S, Gao, Jianjiong, Hellmann, Matthew D, Sauter, Jennifer L, Shah, Sohrab P

“…Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer (NSCLC); however, identifying robust predictive biomarkers remains…”
Get full text

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status by Ricciuti, Biagio, Arbour, Kathryn C, Lin, Jessica J, Vajdi, Amir, Vokes, Natalie, Hong, Lingzhi, Zhang, Jianjun, Tolstorukov, Michael Y, Li, Yvonne Y, Spurr, Liam F, Cherniack, Andrew D, Recondo, Gonzalo, Lamberti, Giuseppe, Wang, Xinan, Venkatraman, Deepti, Alessi, Joao V, Vaz, Victor R, Rizvi, Hira, Egger, Jacklynn, Plodkowski, Andrew J, Khosrowjerdi, Sara, Digumarthy, Subba, Park, Hyesun, Vaz, Nuno, Nishino, Mizuki, Sholl, Lynette M, Barbie, David, Altan, Mehmet, Heymach, John V, Skoulidis, Ferdinandos, Gainor, Justin F, Hellmann, Matthew D, Awad, Mark M

“…STK11 and KEAP1 mutations (STK11 mutant [STK11 ] and KEAP1 ) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been…”
Get more information

Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer by Chan, Joseph M., Quintanal-Villalonga, Álvaro, Gao, Vianne Ran, Xie, Yubin, Allaj, Viola, Chaudhary, Ojasvi, Masilionis, Ignas, Egger, Jacklynn, Chow, Andrew, Walle, Thomas, Mattar, Marissa, Yarlagadda, Dig V.K., Wang, James L., Uddin, Fathema, Offin, Michael, Ciampricotti, Metamia, Qeriqi, Besnik, Bahr, Amber, de Stanchina, Elisa, Bhanot, Umesh K., Lai, W. Victoria, Bott, Matthew J., Jones, David R., Ruiz, Arvin, Baine, Marina K., Li, Yanyun, Rekhtman, Natasha, Poirier, John T., Nawy, Tal, Sen, Triparna, Mazutis, Linas, Hollmann, Travis J., Pe'er, Dana, Rudin, Charles M.

“…Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N,…”
Get full text

Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events by Luo, Jia, Beattie, Jason A, Fuentes, Paige, Rizvi, Hira, Egger, Jacklynn V, Kern, Jeffrey A, Leung, Donald Y M, Lacouture, Mario E, Kris, Mark G, Gambarin, Maya, Santomasso, Bianca D, Faleck, David M, Hellmann, Matthew D

“…The optimal management for immune-related adverse events (irAEs) in patients who do not respond or become intolerant to steroids is unclear. Guidelines suggest…”
Get more information

Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset by Febres-Aldana, Christopher A, Chang, Jason C, Ptashkin, Ryan, Wang, Yuhan, Gedvilaite, Erika, Baine, Marina K, Travis, William D, Ventura, Katia, Bodd, Francis, Yu, Helena A, Quintanal-Villalonga, Alvaro, Lai, W Victoria, Egger, Jacklynn V, Offin, Michael, Ladanyi, Marc, Rudin, Charles M, Rekhtman, Natasha

“…RB1 mutations and loss of retinoblastoma (Rb) expression represent consistent but not entirely invariable hallmarks of small cell lung cancer (SCLC). The…”
Get full text

Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation by Quintanal-Villalonga, Alvaro, Taniguchi, Hirokazu, Zhan, Yingqian A, Hasan, Maysun M, Chavan, Shweta S, Meng, Fanli, Uddin, Fathema, Manoj, Parvathy, Donoghue, Mark T A, Won, Helen H, Chan, Joseph M, Ciampricotti, Metamia, Chow, Andrew, Offin, Michael, Chang, Jason C, Ray-Kirton, Jordana, Tischfield, Sam E, Egger, Jacklynn, Bhanot, Umesh K, Linkov, Irina, Asher, Marina, Sinha, Sonali, Silber, Joachim, Iacobuzio-Donahue, Christine A, Roehrl, Michael H, Hollmann, Travis J, Yu, Helena A, Qiu, Juan, de Stanchina, Elisa, Baine, Marina K, Rekhtman, Natasha, Poirier, John T, Loomis, Brian, Koche, Richard P, Rudin, Charles M, Sen, Triparna

“…Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to…”
Get more information

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC by Alessi, Joao V, Elkrief, Arielle, Ricciuti, Biagio, Wang, Xinan, Cortellini, Alessio, Vaz, Victor R, Lamberti, Giuseppe, Frias, Rosa L, Venkatraman, Deepti, Fulgenzi, Claudia A M, Pecci, Federica, Recondo, Gonzalo, Di Federico, Alessandro, Barrichello, Adriana, Park, Hyesun, Nishino, Mizuki, Hambelton, Grace M, Egger, Jacklynn V, Ladanyi, Marc, Digumarthy, Subba, Johnson, Bruce E, Christiani, David C, Lin, Xihong, Gainor, Justin F, Lin, Jessica J, Pinato, David J, Schoenfeld, Adam J, Awad, Mark M

“…Although programmed cell death protein 1 and programmed death-ligand 1 (PD-L1) blockade in combination with platinum-doublet chemotherapy has become a mainstay…”
Get more information

Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer by Schoenfeld, Adam J, Rizvi, Hira A, Memon, Danish, Shaverdian, Narek, Bott, Matthew J, Sauter, Jennifer L, Tsai, C Jillian, Lihm, Jayon, Hoyos, David, Plodkowski, Andrew J, Perez-Johnston, Rocio, Sawan, Peter, Egger, Jacklynn V, Greenbaum, Benjamin D, Rimner, Andreas, Riely, Gregory J, Rudin, Charles M, Rusch, Valerie W, Gomez, Daniel R, Hellmann, Matthew D

“…Clinical patterns and the associated optimal management of acquired resistance to PD-(L)1 blockade are poorly understood. All cases of metastatic lung cancer…”
Get full text

Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts by Caeser, Rebecca, Egger, Jacklynn V., Chavan, Shweta, Socci, Nicholas D., Jones, Caitlin Byrne, Kombak, Faruk Erdem, Asher, Marina, Roehrl, Michael H., Shah, Nisargbhai S., Allaj, Viola, Manoj, Parvathy, Tischfield, Sam E., Kulick, Amanda, Meneses, Maximiliano, Iacobuzio-Donahue, Christine A., Lai, W. Victoria, Bhanot, Umeshkumar, Baine, Marina K., Rekhtman, Natasha, Hollmann, Travis J., de Stanchina, Elisa, Poirier, John T., Rudin, Charles M., Sen, Triparna

“…Access to clinically relevant small cell lung cancer (SCLC) tissue is limited because surgical resection is rare in metastatic SCLC. Patient-derived xenografts…”
Get full text

Multimodality Therapy in Patients With Primary Pericardial Mesothelioma by Offin, Michael, De Silva, Dilanka L, Sauter, Jennifer L, Egger, Jacklynn V, Yorke, Ellen, Adusumilli, Prasad S, Rimner, Andreas, Rusch, Valerie W, Zauderer, Marjorie G

“…Primary pericardial mesothelioma (PPM) has no accepted standard-of-care treatment options with management and outcomes often extrapolated from diffuse pleural…”
Get more information

Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library by Offin, Michael, Sauter, Jennifer L, Tischfield, Sam E, Egger, Jacklynn V, Chavan, Shweta, Shah, Nisargbhai S, Manoj, Parvathy, Ventura, Katia, Allaj, Viola, de Stanchina, Elisa, Travis, William, Ladanyi, Marc, Rimner, Andreas, Rusch, Valerie W, Adusumilli, Prasad S, Poirier, John T, Zauderer, Marjorie G, Rudin, Charles M, Sen, Triparna

“…Diffuse pleural mesothelioma (DPM) is an aggressive malignancy that, despite recent treatment advances, has unacceptably poor outcomes. Therapeutic research in…”
Get full text

Phosphorylation of the Retinoblastoma protein (Rb) on serine-807 is required for association with Bax by Antonucci, Lisa A, Egger, Jacklynn V, Krucher, Nancy A

“…The recent finding that the Retinoblastoma protein (Rb) is able to regulate apoptosis in a non-transcriptional manner directly at the mitochondria by…”
Get full text

Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation by Quintanal-Villalonga, Alvaro, Taniguchi, Hirokazu, Zhan, Yingqian A, Hasan, Maysun M, Chavan, Shweta S, Meng, Fanli, Uddin, Fathema, Allaj, Viola, Manoj, Parvathy, Shah, Nisargbhai S, Chan, Joseph M, Ciampricotti, Metamia, Chow, Andrew, Offin, Michael, Ray-Kirton, Jordana, Egger, Jacklynn D, Bhanot, Umesh K, Linkov, Irina, Asher, Marina, Roehrl, Michael H, Ventura, Katia, Qiu, Juan, de Stanchina, Elisa, Chang, Jason C, Rekhtman, Natasha, Houck-Loomis, Brian, Koche, Richard P, Yu, Helena A, Sen, Triparna, Rudin, Charles M

“…Lineage plasticity, the ability to transdifferentiate among distinct phenotypic identities, facilitates therapeutic resistance in cancer. In lung…”
Get full text

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer by Elkrief, Arielle, Ricciuti, Biagio, Alessi, Joao V, Fei, Teng, Kalvin, Hannah L, Egger, Jacklynn V, Rizvi, Hira, Thummalapalli, Rohit, Lamberti, Giuseppe, Plodkowski, Andrew, Hellmann, Matthew D, Kris, Mark G, Arcila, Maria E, Baine, Marina K, Rudin, Charles M, Lito, Piro, Ladanyi, Marc, Schoenfeld, Adam J, Riely, Gregory J, Awad, Mark M, Arbour, Kathryn C

“…Abstract Background Direct KRASG12C inhibitors are approved for patients with non-small cell lung cancers (NSCLC) in the second-line setting. The…”
Get full text

Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb by Egger, Jacklynn V., Lane, Maria V., Antonucci, Lisa A., Dedi, Brixhilda, Krucher, Nancy A.

“…The tumor suppressor Retinoblastoma (Rb) protein is highly phosphorylated in cancer cells largely due to the overexpression of cyclins or the loss of…”
Get full text

Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer by Elkrief, Arielle, Montesion, Meagan, Sivakumar, Smruthy, Hale, Caryn, Bowman, Anita S, Begüm Bektaş, Ayyüce, Bradic, Martina, Kang, Wenfei, Chan, Eric, Gogia, Pooja, Manova-Todorova, Katia, Mata, Douglas A, Egger, Jacklynn V, Rizvi, Hira, Socci, Nicolas D, Kelly, Daniel W, Rosiek, Eric, Meng, Fanli, Tam, Grittney, Fan, Ning, Drilon, Alexander, Yu, Helena A, Riely, Gregory J, Rekhtman, Natasha, Quintanal Villalonga, Álvaro, Dogan, Snjezana, Bhanot, Umesh, Gönen, Mithat, Loomis, Brian, Hellmann, Matthew D, Schoenfeld, Adam J, Ladanyi, Marc, Rudin, Charles M, Vanderbilt, Chad M

“…The impact of the intratumoral microbiome on immune checkpoint inhibitor (ICI) efficacy in patients with non-small-cell lung cancer (NSCLC) is unknown…”
Get full text

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study by Elkrief, Arielle, Alessi, Joao M Victor, Ricciuti, Biagio, Brown, Samantha, Rizvi, Hira, Preeshagul, Isabel R, Wang, Xinan, Pecci, Federica, Di Federico, Alessandro, Lamberti, Giuseppe, Egger, Jacklynn V, Chaft, Jamie E, Rudin, Charles M, Riely, Gregory J, Kris, Mark G, Ladanyi, Marc, Chen, Yuan, Hellmann, Matthew D, Shen, Ronglai, Awad, Mark M, Schoenfeld, Adam J

“…BackgroundSingle-agent PD-(L)1 blockade (IO) alone or in combination with chemotherapy (Chemotherapy-IO) is approved first-line therapies in patients with…”
Get full text